Smad4在术后化疗的Ⅱ期结肠癌患者中的表达及临床意义  

The expression and clinical significance of Smad4 in stage Ⅱ colon cancer patients treated with adjuvant chemotherapy after surgery

作　　者：刘岩青[1] 盛吉章[2] 孙凤莉[1] 刘春玲[1] 赵磊[2] 杨文华[1] 戴殿禄[1] 

机构地区：[1]河北省沧州市中心医院肿瘤外二科,河北沧州061001 [2]河北省沧州市中心医院心内科,河北沧州061001

出　　处：《中国医刊》2016年第1期60-64,共5页Chinese Journal of Medicine

摘　　要：目的探讨Smad4在术后辅助化疗的Ⅱ期结肠癌患者中的表达及其临床意义。方法随机选择接受手术治疗同时术后行辅助化疗的96例Ⅱ期结肠癌患者,将其分为复发组(32例)和未复发组(64例)。分别采用实时定量聚合酶链反应和免疫组织化学方法检测Smad4 mRNA和蛋白的表达。计数资料之间用x^2检验比较差异,用Kaplan-Miere和Cox比例风险模型分析Smad4和结肠癌患者无病生存之间的关系。结果 Smad4 mRNA和蛋白在复发组肿瘤组织中的表达明显低于在未复发组肿瘤组织中的表达,两者相比差异有显著性(P<0.05)。Smad4缺失及下降者化疗后5年无瘤生存率显著降低。结论 Smad4基因表达可能是影响术后化疗的Ⅱ期结肠癌患者无病生存时间的独立预后因素。Objective To investigate the expression of Smad4 and its clinical significance in stage Ⅱ colon cancer patients who received adjuvant chemotherapy after surgery. Method 96 stage Ⅱpatients who were treated with adjuvant chemotherapy after surgery were enrolled, it was divided into two groups： recurrence group （32 cases） and non-recurrence group （64 cases）. The expression of Smad4 mRNA and protein was detected by real-time quantitative polymerase chain reaction （real-time PCR） and immunohistochemistry. Chi- square test was used; Kaplan-Miere survival curve and Cox proportional hazard model evaluated the hazard ratio of disease-free survival （DFS）. Result The expression level of Smad4 mRNA and protein in relapse patients were significantly lower than that in non-relapse group different（P〈0.05）. The 5-years DFS decreased significantly in cases with negative or lower expression of Smad4. Conclusion Smad4 is an independent prognostic factor for DFS in Stage H colon cancer patients who were treated with adiuvant chemotherapy after surgery.

关 键 词：SMAD4 结肠癌 化疗 

分 类 号：R735.35[医药卫生—肿瘤]